| Uitgebreide indicatie |
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with:
- as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)
- combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).
|